• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.

作者信息

Cassaday Ryan D, Marks David I, DeAngelo Daniel J, Jabbour Elias J, Advani Anjali S, O'Brien Susan, Wang Tao, Neuhof Alexander, Vandendries Erik, Kantarjian Hagop M, Stock Wendy, Stelljes Matthias

机构信息

University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

University Hospitals Bristol, Bristol, UK.

出版信息

Br J Haematol. 2020 Nov;191(3):e77-e81. doi: 10.1111/bjh.17029. Epub 2020 Aug 17.

DOI:10.1111/bjh.17029
PMID:32805058
Abstract
摘要

相似文献

1
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.使用奥英妥珠单抗治疗的复发或难治性急性淋巴细胞白血病患者的周期数对治疗结果的影响
Br J Haematol. 2020 Nov;191(3):e77-e81. doi: 10.1111/bjh.17029. Epub 2020 Aug 17.
2
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.INO-VATE 试验中的伊妥珠单抗奥唑米星治疗复发/难治性急性淋巴细胞白血病：根据基线 CD22 评估 CD22 药效动力学、疗效和安全性
Clin Cancer Res. 2021 May 15;27(10):2742-2754. doi: 10.1158/1078-0432.CCR-20-2399. Epub 2021 Feb 18.
3
Inotuzumab ozogamicin in acute lymphoblastic leukaemia.
Lancet Oncol. 2019 May;20(5):e248. doi: 10.1016/S1470-2045(19)30218-9. Epub 2019 Apr 4.
4
Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.英妥珠单抗奥唑米星（CMC-544）治疗复发/难治性急性淋巴细胞白血病和非霍奇金淋巴瘤的疗效和安全性：系统评价和荟萃分析。
Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):e227-e247. doi: 10.1016/j.clml.2020.12.008. Epub 2020 Dec 17.
5
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.新型药物在复发/难治性 B 细胞急性淋巴细胞白血病中的应用：blinatumomab 和 inotuzumab ozogamicin 作为一线或二线新型药物治疗复发/难治性急性淋巴细胞白血病的疗效可能相当。
Cancer. 2021 Apr 1;127(7):1039-1048. doi: 10.1002/cncr.33340. Epub 2020 Dec 1.
6
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.在 III 期 INO-VATE 试验中，采用奥加米星治疗复发/难治性急性淋巴细胞白血病患者的微小残留病状态的影响。
Leuk Res. 2020 Jan;88:106283. doi: 10.1016/j.leukres.2019.106283. Epub 2019 Nov 25.
7
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.依妥珠单抗奥滨尤妥珠单抗对比既往治疗复发或难治性急性淋巴细胞白血病：来自随机、3 期 INO-VATE 研究的最终报告和长期生存随访。
Cancer. 2019 Jul 15;125(14):2474-2487. doi: 10.1002/cncr.32116. Epub 2019 Mar 28.
8
Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.因诺妥珠单抗奥佐米星在法国复发或难治性CD22阳性B细胞急性淋巴细胞白血病儿科患者中的同情用药。
Br J Haematol. 2020 Jul;190(1):e53-e56. doi: 10.1111/bjh.16732. Epub 2020 May 18.
9
Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling.依妥珠单抗奥加米星对采用 QTc-浓度建模的血液恶性肿瘤患者 QT 间期的影响。
Br J Clin Pharmacol. 2019 Mar;85(3):590-600. doi: 10.1111/bcp.13832. Epub 2019 Jan 21.
10
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.依妥珠单抗奥佐米星治疗复发/难治性急性淋巴细胞白血病：疾病负担的结果。
Blood Cancer J. 2020 Aug 7;10(8):81. doi: 10.1038/s41408-020-00345-8.

引用本文的文献

1
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.INO-CD22：一项关于奥英妥珠单抗在复发/难治性成人急性淋巴细胞白血病患者中的安全性和有效性的多中心真实世界研究。
Cancer. 2025 Apr 1;131(7):e35820. doi: 10.1002/cncr.35820.
2
CIBMTR Registry Data on Inotuzumab Ozogamicin Treatment in Patients with ALL Who Proceeded to Hematopoietic Stem Cell Transplant-A Podcast.CIBMTR登记处关于接受造血干细胞移植的急性淋巴细胞白血病患者使用奥英妥珠单抗治疗的数据——播客
Target Oncol. 2025 May;20(3):371-374. doi: 10.1007/s11523-025-01129-5. Epub 2025 Mar 20.
3
Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study.
伊尼妥单抗奥唑米星当前获批剂量及更低起始剂量在复发或难治性成人急性淋巴细胞白血病患者中的疗效与安全性：一项IV期研究
Haematologica. 2025 Aug 1;110(8):1736-1746. doi: 10.3324/haematol.2024.286091. Epub 2025 Jan 30.
4
Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients.成人复发性急性淋巴细胞白血病的治疗。
Curr Treat Options Oncol. 2024 Aug;25(8):993-1010. doi: 10.1007/s11864-024-01213-4. Epub 2024 Jun 25.
5
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.HA-1 靶向 T 细胞受体 T 细胞疗法治疗造血干细胞移植后复发性白血病。
Blood. 2024 Sep 5;144(10):1069-1082. doi: 10.1182/blood.2024024105.
6
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.挽救性治疗中采用 mini-hyper-CVD 和奥加米星单抗联合或不联合blinatumomab 治疗前 B 急性淋巴细胞白血病的结果。
J Hematol Oncol. 2023 May 2;16(1):44. doi: 10.1186/s13045-023-01444-2.